Supplementary Figure 4: Deregulated MYCN binding at promoters and enhancers in the TH-MYCN genetically engineered neuroblastoma mouse model. | Nature Genetics

Supplementary Figure 4: Deregulated MYCN binding at promoters and enhancers in the TH-MYCN genetically engineered neuroblastoma mouse model.

From: Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma

Supplementary Figure 4

a, Immunohistochemistry staining of MYCN and a corresponding no-stain control in celiac ganglia, TH-MYCN tumors, and spleen. b, Meta track representation of H3K27ac ChIP–seq signal (RPM/bp) in ganglia (celiac and superior cervical) and TH-MYCN tumors as well as MYCN ChIP–seq signal in TH-MYCN tumors at the indicated loci. c, Meta track representation of H3K27ac ChIP–seq signal (RPM/bp) in ganglia (celiac and superior cervical) and TH-MYCN tumors as well as MYCN ChIP–seq signal in TH-MYCN tumors at an upstream Id2 enhancer. d, Meta track representation of H3K27ac ChIP–seq signal (RPM/bp) in ganglia (celiac and superior cervical) and TH-MYCN tumors as well as MYCN ChIP–seq signal in TH-MYCN tumors at the indicated loci. e, Meta track representation of MYCN and H3K27ac ChIP–seq signal (RPM/bp) across four neuroblastoma cell lines at the indicated loci. f, Pie chart showing the percentage of MYCN binding sites in human neuroblastoma cell lines that exhibit H3K27ac signal in TH-MYCN tumors and/or ganglia at promoters (left) and enhancers (right).

Back to article page